Cargando…

PReS-FINAL-2140: Neutropenia with Tocilizumab (TCZ) treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis (SJIA)

Detalles Bibliográficos
Autores principales:	De Benedetti, F, Brunner, HI, Baildam, E, Burgos-Vargas, R, Horneff, G, Huppertz, HI, Minden, K, Myones, BL, Onel, K, Wang, J, Bharucha, K, Lovell, D, Martini, A, Ruperto, N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043208/ http://dx.doi.org/10.1186/1546-0096-11-S2-P152

Ejemplares similares

PReS-FINAL-2134: Assessment of radiographic progression in patients (pts) with systemic juvenile idiopathic arthritis (sjia) treated with tocilizumab (TCZ): 2-year results from the tender trial
por: Malattia, C, et al.
Publicado: (2013)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data
por: De Benedetti, F, et al.
Publicado: (2011)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
por: De Benedetti, Fabrizio, et al.
Publicado: (2012)

PReS-FINAL-2180: Efficacy and safety of tocilizumab (TCZ) in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH
por: De Benedetti, F, et al.
Publicado: (2013)

PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
por: Lu, P, et al.
Publicado: (2013)

PReS-FINAL-2188: Insulin sensitivity is improved in sjia children with insulin resistance after tocilizumab treatment: results from the tender study
por: Mirjafari, H, et al.
Publicado: (2013)

Maintenance of efficacy of canakinumab in SJIA at the individual patient level in a 12-week pooled dataset
por: Ravelli, A, et al.
Publicado: (2014)

Use of the JADAS criteria to assess efficacy of canakinumab in patients with SJIA – an analysis of 12-week pooled data
por: Ravelli, A, et al.
Publicado: (2014)

PReS-FINAL-2158: Effect of canakinumab on functional ability and health-related quality of life in systemic juvenile idiopathic arthritis (SJIA) patients
por: Quartier, P, et al.
Publicado: (2013)

Predictors of response in patients with active systemic JIA (SJIA) receiving canakinumab: an exploratory analysis of pooled 12-week data
por: Ruperto, N, et al.
Publicado: (2014)

Efficacy of canakinumab in biologic-naïve versus previously biologic-exposed SJIA patients: a 12 week pooled post-hoc analysis
por: Quartier, P, et al.
Publicado: (2014)

PReS-FINAL-2156: Analysis of gene expression and inflammation biomarkers in systemic juvenile idiopathic arthritis (SJIA) patients on canakinumab therapy
por: Nirmala, N, et al.
Publicado: (2013)

PReS-FINAL-2139: Tapering and withdrawal of tocilizumab in patients with systemic JIA in inactive disease: results from an alternative dosing regimen in the tender study
por: De Benedetti, F, et al.
Publicado: (2013)

Safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis
por: Horneff, G, et al.
Publicado: (2015)

Open label multicenter study of once weekly Etanercept 0.8 mg/kg in active polyarticular Juvenile idiopathic arthritis (JIA)
por: Horneff, G, et al.
Publicado: (2008)

Reduction in missed school days and improvement in parent activity participation in children with juvenile idiopathic arthritis treated with abatacept
por: Ruperto, N, et al.
Publicado: (2008)

Outcome of repeat dosing of sJIA patients with tocilizumab in one UK centre
por: Livermore, P, et al.
Publicado: (2008)

Tocilizumab (TCZ) may be an effective treatment for poly-juvenile idiopathic arthritis (pJIA) as for rheumatoid arthritis (RA)
por: Yamaguchi, Ken-ichi, et al.
Publicado: (2012)

Hemoculture and Polymerase Chain Reaction Using Primers TCZ1/TCZ2 for the Diagnosis of Canine and Feline Trypanosomiasis
por: Eloy, Luciano José, et al.
Publicado: (2012)

PReS-FINAL-2001: The impact of adalimumab on growth in patients with juvenile idiopathic arthritis
por: Ruperto, N, et al.
Publicado: (2013)

P02-029 - CAPS or SJIA
por: Alekseeva, E, et al.
Publicado: (2013)

PReS-FINAL-2152: Biomarkers as predictors of early inactive disease in children with juvenile idiopathic arthritis
por: Lavric, M, et al.
Publicado: (2013)

PReS-FINAL-2070: Efficacy of biologic treatments in juvenile idiopathic arthritis with a polyarticular course: an indirect comparison
por: Sawyer, L, et al.
Publicado: (2013)

Phase III, multi-centre, randomised, double blind, Placebo-controlled study for treatment of juvenile ankylosing spondylitis (AS) with Adalimumab
por: Horneff, G, et al.
Publicado: (2011)

Tocilizumab: Neutropenia: case report
Publicado: (2020)

Tocilizumab: Neutropenia: case report
Publicado: (2021)

PReS-FINAL-2179: Efficacy and safety of adalimumab in pediatric patients with enthesitis related arthritis
por: Burgos-Vargas, R, et al.
Publicado: (2013)

PReS-FINAL-2040: Outcome of macrophage activation syndrom (MAS) in systemic juvenile idiopatic arthritis (SJIA) in non biologic treated patient
por: Lazarevic, DS, et al.
Publicado: (2013)

Tocilizumab (TCZ) Decreases Angiogenesis in Rheumatoid Arthritis Through Its Regulatory Effect on miR-146a-5p and EMMPRIN/CD147
por: Zisman, Devy, et al.
Publicado: (2021)

Mitochondrial and oxidative stress genes are differentially expressed in neutrophils of sJIA patients treated with tocilizumab: a pilot microarray study
por: Omoyinmi, Ebun, et al.
Publicado: (2016)

PReS-FINAL-2178: Clinical and microarray follow-up of SJIA patients treated with anakinra over the past 10 years in a single institution
por: Punaro, M, et al.
Publicado: (2013)

COLLABORATION FRAMEWORK AGREEMENT KN 2140 DG
por: THE EUROPEAN ORGANIZATION FOR NUCLEAR RESEARCH, CERN, et al.
Publicado: (2013)

Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab
por: Horneff, Gerd, et al.
Publicado: (2016)

Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
por: Ruperto, Nicolino, et al.
Publicado: (2021)

ADDENDUM No.1TO COLLABORATION AGREEMENT KN2140/DG
por: The European Organization for Nuclear Research, CERN, et al.
Publicado: (2014)

2140: Estimating microscopic structures of glomeruli in renal pathology
por: Sarder, Pinaki, et al.
Publicado: (2018)

IL-18 production upon s100 stimulation is reduced in active sJIA patients compared to sJIA patients in remission and healthy controls
por: Haar, Nienke Ter, et al.
Publicado: (2014)

PReS-FINAL-2110: Tocilizumab for patients with oligoarticular juvenile idiopathic arthritis refractory to conventional therapy
por: Sato, T, et al.
Publicado: (2013)

Tocilizumab: Off-label use and neutropenia: case report
Publicado: (2021)

Tocilizumab: Neutropenia following off-label use: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2meenud654qf4clc8do3af63jk